MarketCap
Facebook
X
TelegramQuarterly report 2026-Q3
added 05-13-2026
Aytu BioScience Total Non Current Liabilities 2011-2026 | AYTU
Annual Total Non Current Liabilities Aytu BioScience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.1 M | 28.2 M | 28.1 M | - | - | 29.5 M | 22.3 M | 4.24 M | 7.39 M | 4.15 M | 1.13 M | 554 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 42.1 M | 554 K | 16.8 M |
Quarterly Total Non Current Liabilities Aytu BioScience
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.6 M | 42.2 M | 35.8 M | 42.2 M | 35.8 M | 42.1 M | 18.6 M | 21.4 M | 24.8 M | 28.2 M | 14.4 M | 34.2 M | - | 28.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 42.2 M | 14.4 M | 29.6 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
79.1 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
158 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
189 M | $ 1.69 | 2.74 % | $ 198 M | USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M | China |
 |
Celldex Therapeutics
CLDX
|
17.3 M | $ 31.72 | 2.82 % | $ 2.11 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
622 M | $ 93.62 | 1.49 % | $ 22.6 B | Germany |
 |
AstraZeneca PLC
AZN
|
34.7 B | - | - | $ 96.9 B |  Britain |
 |
CRISPR Therapeutics AG
CRSP
|
70.2 M | $ 53.82 | 4.33 % | $ 4.84 B |  Schweiz |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
7.32 M | - | 0.74 % | $ 768 M |  Israel |
 |
Compugen Ltd.
CGEN
|
31.3 M | $ 2.76 | 3.96 % | $ 258 M | Israel |
 |
Abcam plc
ABCM
|
128 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
64 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
645 K | - | -18.52 % | $ 27.3 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
383 M | $ 0.75 | 9.65 % | $ 34.3 M | Israel |
 |
Esperion Therapeutics
ESPR
|
355 M | $ 3.13 | 0.16 % | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
4.56 M | $ 31.98 | 2.21 % | $ 861 M | USA |
 |
Affimed N.V.
AFMD
|
13.4 M | - | -34.95 % | $ 21.5 M | Germany |
|
Forte Biosciences
FBRX
|
10.5 M | $ 21.97 | 0.14 % | $ 284 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Celyad Oncology SA
CYAD
|
4.97 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
22.3 M | - | -7.31 % | $ 87 M | USA |
 |
Galectin Therapeutics
GALT
|
52 K | $ 2.72 | -2.69 % | $ 174 M | USA |
 |
Generation Bio Co.
GBIO
|
132 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
8.95 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
497 K | - | - | $ 7.46 M | Israel |
 |
Grifols, S.A.
GRFS
|
10.6 B | $ 8.02 | 0.06 % | $ 5.45 B |  Spain |
 |
Hutchison China MediTech Limited
HCM
|
46.8 M | $ 11.78 | 0.26 % | $ 10.1 B | China |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.06 M | - | -4.36 % | $ 27 M | USA |
 |
Heron Therapeutics
HRTX
|
14.6 M | $ 0.9 | 1.45 % | $ 150 M | USA |
 |
Gracell Biotechnologies
GRCL
|
51.9 M | - | - | $ 3.37 B | China |
 |
ImmuCell Corporation
ICCC
|
11.5 M | $ 10.62 | 1.1 % | $ 95.9 M | USA |
 |
Anika Therapeutics
ANIK
|
26.1 M | $ 14.67 | -1.48 % | $ 210 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
14 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 3.35 | -2.62 % | $ 5.51 M | Israel |